Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.336
Sell
RSI(14)
40.096
Neutral
STOCH(KDJ)(9,3,3)
19.709
Neutral
ATR(14)
0.574
High Vlolatility
CCI(14)
-112.927
Sell
Williams %R
77.676
Sell
TRIX(12,20)
-0.160
Sell
StochRSI(14)
72.152
Buy
Innoviva Inc
INVA19.770USD
+0.260+1.33%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.48BMarket Cap
10.02P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Innoviva Inc
Currency: USD Updated: 2025-12-24Key Insights
Innoviva Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 31/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 32.25.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Innoviva Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
32.250
Target Price
+53.57%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Innoviva Inc Highlights
StrengthsRisks
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Fairly Valued
The company’s latest PE is 10.02, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 75.62M shares, decreasing 2.98% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 4.29K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-24The current financial score of Innoviva Inc is 9.09, ranking 18/158 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 107.80M, representing a year-over-year increase of 20.44%, while its net profit experienced a year-over-year increase of 7312.04%.
Score
Financials
9.92
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.76
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.77
Innoviva Inc's Company Valuation
Currency: USD Updated: 2025-12-24The current valuation score of Innoviva Inc is 7.66, ranking 53/158 in the Pharmaceuticals industry. Its current P/E ratio is 10.02, which is 407.93% below the recent high of 50.90 and 329.47% above the recent low of -22.99.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 31/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-24The current earnings forecast score of Innoviva Inc is 7.50, ranking 103/158 in the Pharmaceuticals industry. The average price target for Innoviva Inc is 33.00, with a high of 45.00 and a low of 18.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
32.250
Target Price
+53.57%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Innoviva Inc
INVA
4
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-24The current price momentum score of Innoviva Inc is 6.64, ranking 113/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 21.52 and the support level at 18.66, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
19.866
Sell
MA10
20.069
Sell
MA20
20.550
Sell
MA50
19.933
Sell
MA100
19.590
Buy
MA200
19.278
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-24The current institutional shareholding score of Innoviva Inc is 10.00, ranking 1/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 101.14%, representing a quarter-over-quarter decrease of 8.13%. The largest institutional shareholder is The Vanguard, holding a total of 7.08M shares, representing 9.47% of shares outstanding, with 5.33% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Dimensional Fund Advisors, L.P.
Sarissa Capital Management, L.P.
State Street Investment Management (US)
Putnam Investment Management, L.L.C.
Arrowstreet Capital, Limited Partnership
American Century Investment Management, Inc.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-24The current risk assessment score of Innoviva Inc is 8.03, ranking 36/158 in the Pharmaceuticals industry. The company's beta value is 0.44. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.44
VaR
+2.53%
240-Day Maximum Drawdown
+23.53%
240-Day Volatility
+31.43%
Return
Best Daily Return
60 days
+12.89%
120 days
+12.89%
5 years
+13.71%
Worst Daily Return
60 days
-4.10%
120 days
-4.10%
5 years
-7.83%
Sharpe Ratio
60 days
+0.59
120 days
+0.34
5 years
+0.51
Risk Assessment
Maximum Drawdown
240 days
+23.53%
3 years
+100.00%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+0.61
3 years
+0.20
5 years
+0.12
Skewness
240 days
+2.35
3 years
+1.17
5 years
+0.98
Volatility
Realised Volatility
240 days
+31.43%
5 years
--
Standardised True Range
240 days
+2.52%
5 years
+2.25%
Downside Risk-Adjusted Return
120 days
+78.82%
240 days
+78.82%
Maximum Daily Upside Volatility
60 days
+35.00%
Maximum Daily Downside Volatility
60 days
+17.53%
Liquidity
Average Turnover Rate
60 days
+1.44%
120 days
+1.42%
5 years
--
Turnover Deviation
20 days
+16.17%
60 days
+30.02%
120 days
+28.19%
Peer Comparison
Pharmaceuticals
Innoviva Inc
INVA
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.78 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Innoviva Inc?
The TradingKey Stock Score provides a comprehensive assessment of Innoviva Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Innoviva Inc’s performance and outlook.
How do we generate the financial health score of Innoviva Inc?
To generate the financial health score of Innoviva Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Innoviva Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Innoviva Inc.
How do we generate the company valuation score of Innoviva Inc?
To generate the company valuation score of Innoviva Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Innoviva Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Innoviva Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Innoviva Inc.
How do we generate the earnings forecast score of Innoviva Inc?
To calculate the earnings forecast score of Innoviva Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Innoviva Inc’s future.
How do we generate the price momentum score of Innoviva Inc?
When generating the price momentum score for Innoviva Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Innoviva Inc’s prices. A higher score indicates a more stable short-term price trend for Innoviva Inc.
How do we generate the institutional confidence score of Innoviva Inc?
To generate the institutional confidence score of Innoviva Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Innoviva Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Innoviva Inc.
How do we generate the risk management score of Innoviva Inc?
To assess the risk management score of Innoviva Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Innoviva Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Innoviva Inc.
